🇺🇸 FDA
Patent

US 8257915

Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis

granted A61KA61K31/4545A61K31/4709

Quick answer

US patent 8257915 (Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Aug 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Sep 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 30 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K31/4545, A61K31/4709, A61K45/06, A61P